Dramatic Response to CBD in Ovarian Cancer Patient
The National Institute of Health (NIH) published an article documenting a dramatic response using CBD for an ovarian cancer patient. The patient having been diagnosed with metastatic low grade serous ovarian carcinoma who declined a recommended chemotherapy. Instead, opting for a Complementary Alternative Medicine (CAM) therapy that included CBD.
The article abstract highlights two (2) notable observations that patients should discuss with the doctors. First, complementary alternative medicine use is common in women with gynecologic cancers. And Cannabinoid receptors are potential therapeutic targets in ovarian cancer. Hence, discussion with patients is critical regarding the use of alternative therapies.
Low grade serous ovarian cancer (LGSOC)
Low grade serous ovarian cancer is a rare malignancy that is relatively resistant to chemotherapy in comparison to its high-grade counterpart. LGSOC is a rare subtype of serous epithelial ovarian cancer, comprising approximately 10% of all cases of serous carcinoma. Most women are diagnosed with advanced-stage disease, despite its slow growth
The article offers that the management of patients with LGSOC remains a challenge, particularly in the advanced stage and recurrent setting. The current standard of care remains platinum and taxane-based combination chemotherapy, followed by maintenance hormonal therapy. Unfortunately, patients who progress have limited therapeutic options. As a result, being encouraged to consider clinical trials if available. Most of all, note as response rates to chemotherapy in the recurrent setting are less than 5%.
Summary and Observed Results
So here, the authors present the case of a female patient who demonstrated disease response after declining standard therapy. Then in consultation with her doctors, taking a combination of Laetrile and CBD oil. Previous clinical trials in humans have demonstrated no therapeutic effect in cancer patients taking Laetrile. However, basic science studies have identified cannabinoid receptors in ovarian cancer as potential therapeutic targets for cannabinoid use in treating malignancy. This area remains under study. However, the conditions here produced a Dramatic Response to CBD in Ovarian Cancer Patient.
And this case highlights the importance of communication between physicians and their patients regarding the use of alternative therapies.
Takeaways | Dramatic Response to CBD in Ovarian Cancer Patient
LGSOC patients should discuss their treatment options with their Doctors. Recognize that CAM therapy may be an option. Hence, include the article’s findings in the decision process to identify an individual’s treatment plan.
You can read the full article here